🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our last paper: In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded; Our analysis suggests that CGD retains its efficacy independently of the timing of relapse after surgery academic.oup.com/oncolo/advance…

Intermediate-stage HCC: a rapidly evolving treatment landscape of a highly-heterogeneus disease setting. Here we reviewed the state of the art and the putative changes we will encounter in clinical practice due to recent evidence. ⬇️Check this out! andrea casadei gardini Margherita Rimini

PM-CARE trial is active and recruiting at Ospedale San Raffaele ! 📣 multicenter phase Il study that combines radioembolization with immunotherapy and chemotherapy for intrahepatic cholangiocarcinoma. For info contact us at [email protected] andrea casadei gardini Francesca Ratti

I would like to thank Prof. Jean-François Dufour and the Swiss Liver Cancer Foundation for selecting our work " Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atez/Bev " for this brief interview m.youtube.com/watch?v=yxxabg…

On WorldCCADay 2 Series papers and 2 comments on #BTC #CCA #biliarytractcancer #cholangiocarcinoma epidemiology, diagnosis and treatment disparities and inequalities in Europe just published in The Lancet Reg Health-Europe and presented at EASLnews EASL Education #livercancersummit in #Paris

We have launched our 1st clinical Series of 2025 EASL Education in Paris on Biliary tract cancers Explore findings & recommendations in our infographic & read the full Series here: thelancet.com/infographics-d… EASLnews #livercancersummit

📢 HER2 and Biliary Tract Cancer: The Future of Targeted Therapies Our latest article delves into the current landscape and the emerging therapeutic strategies shaping the future of precision medicine. 📖 Read the full article here: link.springer.com/article/10.100…

2L Rego after 1L Atezo-Bev in uHCC (REGONEXT) - Multicenter study in Korea - Single-arm Ph (n=40) - mPFS 3.5 mo, mOS 10.5 mo and ORR 10% - Rapid PD on prior Atezo-Bev was associated with poor Rego outcomes -> Rego may not be enough to overcome poor biology

Results that can only be achieved through networking… When Italian research comes together, it achieves incredible results! 👏 Margherita Rimini Lorenza Rimassa Lorenzo Fornaro

Results of the first real-world study of 1st-line CGD in patients w/ BTC w/ early relapse. Analysis suggests that this group can benefit from CGD in terms of OS, PFS, and ORR, with a good safety profile. andrea casadei gardini #Cholangiocarcinoma #Immunotherapy doi.org/10.1093/oncolo…

🚨 New publication alert! andrea casadei gardini We investigated how early bevacizumab dose/time modifications (eBEVmod) impact the efficacy of Atezolizumab + Bevacizumab in advanced hepatocellular carcinoma (aHCC) treatment in a real-world setting. 📄 Read: authors.elsevier.com/sd/article/S29… 👇

🚨 New in ESMO GI Oncology: In aHCC, early Bevacizumab dose mods = worse outcomes. 💡 <45 mg/kg in 3 months ➡️ ☠️ Higher mortality (HR 3.3) 📉 12-mo survival: 53% vs 77% ✅ Full-dose Beva is crucial with AtezBev. Federico Rossari authors.elsevier.com/sd/article/S29…